SG11202003283TA - Bicyclic compounds for use as rip1 kinase inhibitors - Google Patents
Bicyclic compounds for use as rip1 kinase inhibitorsInfo
- Publication number
- SG11202003283TA SG11202003283TA SG11202003283TA SG11202003283TA SG11202003283TA SG 11202003283T A SG11202003283T A SG 11202003283TA SG 11202003283T A SG11202003283T A SG 11202003283TA SG 11202003283T A SG11202003283T A SG 11202003283TA SG 11202003283T A SG11202003283T A SG 11202003283TA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitors
- bicyclic compounds
- rip1 kinase
- rip1
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570892P | 2017-10-11 | 2017-10-11 | |
| PCT/EP2018/077656 WO2019072942A1 (en) | 2017-10-11 | 2018-10-10 | Bicyclic compounds for use as rip1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003283TA true SG11202003283TA (en) | 2020-05-28 |
Family
ID=63840848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003283TA SG11202003283TA (en) | 2017-10-11 | 2018-10-10 | Bicyclic compounds for use as rip1 kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11673892B2 (en) |
| EP (1) | EP3694858B1 (en) |
| JP (1) | JP7362600B2 (en) |
| KR (1) | KR20200070297A (en) |
| CN (1) | CN111201229A (en) |
| AU (1) | AU2018348930A1 (en) |
| BR (1) | BR112020007067A2 (en) |
| CA (1) | CA3078653A1 (en) |
| CL (1) | CL2020000944A1 (en) |
| CO (1) | CO2020004977A2 (en) |
| CR (1) | CR20200151A (en) |
| IL (1) | IL273443A (en) |
| MA (1) | MA50356A (en) |
| MX (1) | MX2020003439A (en) |
| PE (1) | PE20211246A1 (en) |
| PH (1) | PH12020550253A1 (en) |
| RU (1) | RU2020114670A (en) |
| SG (1) | SG11202003283TA (en) |
| WO (1) | WO2019072942A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548484A1 (en) | 2016-12-02 | 2019-10-09 | H. Hoffnabb-La Roche Ag | Bicyclic amide compounds and methods of use thereof |
| TWI805595B (en) * | 2017-07-14 | 2023-06-21 | 瑞士商赫孚孟拉羅股份公司 | Bicyclic ketone compounds and methods of use thereof |
| MX2020003451A (en) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof. |
| JP2022516651A (en) * | 2019-01-11 | 2022-03-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Bicyclic pyrrorotriazole ketone compounds and their usage |
| CN114591333B (en) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | Preparation method of pyrrolopyrimidine compound |
| WO2023039795A1 (en) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1 kinase inhibitor and use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (en) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1992004343A1 (en) * | 1990-09-04 | 1992-03-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel tetrahydrobenzazole derivative |
| JPH07509250A (en) | 1992-07-27 | 1995-10-12 | アメリカ合衆国 | Targeting liposomes to the blood-brain barrier |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| AU8071698A (en) | 1997-06-13 | 1998-12-30 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| NZ524475A (en) | 2000-08-10 | 2004-11-26 | Pharmacia Italia S | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (en) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation |
| ES2289116T3 (en) | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | NEW DERIVATIVES OF PIRROL AS PHARMACEUTICAL AGENTS. |
| AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| AU2003302676A1 (en) | 2002-12-03 | 2004-06-23 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| CA2677572C (en) | 2007-02-07 | 2012-12-18 | Pfizer Inc. | 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors |
| JP2012051806A (en) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | Imidazolylpyrazine derivative |
| AP2011006034A0 (en) | 2009-07-15 | 2011-12-31 | Janssen Pharmaceuticals Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators. |
| EP2731948B1 (en) | 2011-07-15 | 2015-09-09 | Janssen Pharmaceuticals, Inc. | Novel substituted indole derivatives as gamma secretase modulators |
| JP6267193B2 (en) | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Substituted dipyridylamines and their use |
| MX2015009270A (en) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | 3-substituted pyrazoles and use as dlk inhibitors. |
| TWI648274B (en) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | Heterocyclic guanamines as kinase inhibitors (2) |
| RU2015147601A (en) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | C-Bound Heterocycloalkyl-Substituted Pyrimidines and Their Applications |
| MA38624A1 (en) | 2013-05-01 | 2017-02-28 | Hoffmann La Roche | Biheteroaryl compounds and their uses |
| MX2016008110A (en) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Pyrazole derivatives and uses thereof as inhibitors of dlk. |
| AU2015304851A1 (en) | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
| MA53835A (en) | 2015-07-02 | 2021-08-11 | Hoffmann La Roche | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS FOR THE P.E. TREATMENT OF INFLAMMATORY DISEASES |
| MA44007A (en) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | RECEPTOR INHIBITORS INTERACTING WITH KINASE 1 PROTEIN |
| KR102613433B1 (en) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | Novel phenyl pyridine derivatives and pharmaceutical composition comprising the same |
-
2018
- 2018-10-10 WO PCT/EP2018/077656 patent/WO2019072942A1/en unknown
- 2018-10-10 AU AU2018348930A patent/AU2018348930A1/en not_active Abandoned
- 2018-10-10 BR BR112020007067-0A patent/BR112020007067A2/en not_active Application Discontinuation
- 2018-10-10 CA CA3078653A patent/CA3078653A1/en active Pending
- 2018-10-10 CN CN201880066460.0A patent/CN111201229A/en active Pending
- 2018-10-10 EP EP18785936.8A patent/EP3694858B1/en active Active
- 2018-10-10 SG SG11202003283TA patent/SG11202003283TA/en unknown
- 2018-10-10 MX MX2020003439A patent/MX2020003439A/en unknown
- 2018-10-10 CR CR20200151A patent/CR20200151A/en unknown
- 2018-10-10 MA MA050356A patent/MA50356A/en unknown
- 2018-10-10 JP JP2020520532A patent/JP7362600B2/en active Active
- 2018-10-10 KR KR1020207013188A patent/KR20200070297A/en not_active Application Discontinuation
- 2018-10-10 PE PE2020000378A patent/PE20211246A1/en unknown
- 2018-10-10 RU RU2020114670A patent/RU2020114670A/en unknown
-
2020
- 2020-03-19 IL IL273443A patent/IL273443A/en unknown
- 2020-04-08 CL CL2020000944A patent/CL2020000944A1/en unknown
- 2020-04-09 PH PH12020550253A patent/PH12020550253A1/en unknown
- 2020-04-09 US US16/844,952 patent/US11673892B2/en active Active
- 2020-04-23 CO CONC2020/0004977A patent/CO2020004977A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020536915A (en) | 2020-12-17 |
| IL273443A (en) | 2020-05-31 |
| EP3694858B1 (en) | 2023-01-11 |
| PE20211246A1 (en) | 2021-07-13 |
| AU2018348930A1 (en) | 2020-03-26 |
| CN111201229A (en) | 2020-05-26 |
| RU2020114670A (en) | 2021-11-12 |
| PH12020550253A1 (en) | 2021-02-22 |
| US11673892B2 (en) | 2023-06-13 |
| CR20200151A (en) | 2020-05-23 |
| MX2020003439A (en) | 2020-07-29 |
| MA50356A (en) | 2021-04-21 |
| CO2020004977A2 (en) | 2020-05-05 |
| CA3078653A1 (en) | 2019-04-18 |
| BR112020007067A2 (en) | 2020-10-06 |
| JP7362600B2 (en) | 2023-10-17 |
| EP3694858A1 (en) | 2020-08-19 |
| CL2020000944A1 (en) | 2020-08-21 |
| US20200283446A1 (en) | 2020-09-10 |
| WO2019072942A1 (en) | 2019-04-18 |
| KR20200070297A (en) | 2020-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400003I1 (en) | Compounds useful as kinase inhibitors | |
| IL274540B (en) | Compounds useful for inhibiting cdk7 | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL273443A (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors | |
| GB201522245D0 (en) | Compounds useful as kinase inhibitors |